Navigation Links
Finding the Achilles' Heel of ovarian tumor growth
Date:6/19/2014

A team of scientists, led by principal investigator David D. Schlaepfer, PhD, professor in the Department of Reproductive Medicine at the University of California, San Diego School of Medicine report that small molecule inhibitors to a protein called focal adhesion kinase (FAK) selectively prevent the growth of ovarian cancer cells as tumor spheroids.

The findings come in a pair of studies published online this week in the journals Gynecologic Oncology and Molecular Cancer Therapeutics.

Ovarian cancer is a leading cause of female cancer death in the United States. On average, more than 21,000 women are diagnosed with ovarian cancer each year and 14,270 die. Many women achieve remission, but cancer recurrence rates exceed 75 percent, prompting the need for new treatments.

"Ovarian cancer spreads within a women's peritoneal space through a unique mechanism that involves the survival of small clusters of tumor cells termed spheroids," said Schlaepfer. "Our studies show that FAK signaling functions at the center of a tumor cell survival signaling network."

In the first study, published in Gynecologic Oncology, first author Nina Shah, MD, a gynecological oncology fellow in the Department of Reproductive Medicine, found that ovarian tumor cells with low levels of a tumor suppressor protein, called merlin, displayed heightened sensitivity to FAK inhibitor growth cessation.

"With FAK inhibitor clinical trials already testing a similar linkage in mesothelioma (a rare cancer that affects the protective lining of many internal organs), our results support the hypothesis that protein biomarkers such as merlin may identify those patients who may best respond to FAK inhibitor therapy," said Schlaepfer.

In the second study in Molecular Cancer Therapeutics, first author Isabelle Tancioni PhD, an assistant project scientist at UC San Diego Moores Cancer Center discovered that a network of signals generated by osteopontin a beta-5 integrin receptor used in cell-to-cell signaling and FAK control ovarian cancer spheroid growth. High levels of beta-5 integrin and FAK expression are associated with a poor prognosis for some ovarian cancer patients. "Thus, high levels of beta-5 integrin may serve as a novel biomarker for ovarian carcinoma cells that possess active FAK signaling," said Schlaepfer.

Schlaepfer noted that tumor recurrence and metastasis are responsible for the majority of ovarian cancer-related deaths and said the new findings support ongoing clinical trials of FAK inhibitors as new agents in the fight to prevent ovarian cancer progression.


'/>"/>

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. New findings in breast cancer
2. Kessler Foundation scientists present cognitive research findings at MS dual symposium
3. Researchers present new findings for novel pancreatic cancer vaccine
4. Mayo Clinic urologists present findings at American Urological Association Annual Meeting
5. Finding ways to feed pigs for less
6. Once-Banned Bird Flu Study Yields Sobering Findings
7. Columbus Allergist Dr. Summit Shah Discusses Recent Findings on Food Allergies and Exercise-Induced Anaphylaxis
8. Finding brings scientists 1 step closer to Parkinsons drug
9. Relief for Migraine Sufferers as The Life House Offers New Findings, Free Consults
10. New findings by GW researcher break tanning misconceptions: There is no such thing as a safe tan
11. MRI findings shed light on multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Finding the Achilles' Heel of ovarian tumor growth
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting , ... recently partnered with Heart City Health Center to improve access to ... Heart City Health Center has provided the Elkhart community with access to high ...
(Date:2/10/2016)... TX (PRWEB) , ... February 10, 2016 , ... ... commencement of a master charity program created to assist the local community. Pledging ... with community leaders and nonprofit organizations in the area. Their goal is to ...
(Date:2/10/2016)... Tarzana, CA (PRWEB) , ... February 10, 2016 ... ... Fernando Valley , announces that his office is now offering a variety of ... cheek enhancement, chin enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 Executive Forum, ... 200 of the country’s top healthcare executives to share insights on transformational strategies ... the Forum is the provider-centric perspective, experience, expertise and strategy shared by the ...
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral ... December 31, 2015 on Monday, February 29, 2016 after the market closes. , The ... release at 4:30 PM ET. Investors interested in participating by phone are invited to ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... February 10, 2016 --> --> This ... .  --> Japan .  --> A separate ... With submission, Shire continues to strengthen its ... submission, Shire continues to strengthen its presence ... Shire continues to strengthen its presence ...
(Date:2/10/2016)... -- CSI Specialty Group (CSI) expanded its specialty pharmacy ... Pharmacy Podcast. A free, weekly show, the Specialty Pharmacy ... discussion and context amongst specialty pharmacy peers and professionals. ... The Specialty Pharmacy Podcast, hosted by industry leader ... DiMascio, CHE, CMCE, CPC, is available for streaming and/or ...
(Date:2/10/2016)... , Feb. 10, 2016  CVS Health (NYSE: ... people living in Santa Clara County, CA ... B on the Santa Clara University campus. CVS Pharmacy ... to protect patients against the disease. Students at Santa ... to get vaccinated. In addition, anyone who has had ...
Breaking Medicine Technology: